UBS Group’s ENZON PHARMACEUTICALS INC ENZN Stock Holding History

UBS Group’s Portfolio ENZN Stock Details ENZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-723,072	Closed	-$340K	–	8290
2016 Q1	$340K	Buy	723,072 +29,046	+4%	+$14.2K	﹤0.01%	4084
2015 Q4	$474K	Sell	694,026 -49,181	-7%	-$39K	﹤0.01%	3997
2015 Q3	$721K	Buy	743,207 +35,286	+5%	+$43.4K	﹤0.01%	3623
2015 Q2	$850K	Sell	707,921 -1,100	-0.2%	-$1.4K	﹤0.01%	3696
2015 Q1	$752K	Buy	709,021 +1,070	+0.2%	+$1.11K	﹤0.01%	3817
2014 Q4	$771K	Buy	+707,951	New	+$743K	﹤0.01%	3784

Other funds holding ENZN

California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Ancora Advisors Cleveland, Ohio $4.7B AUM 19.05% 1-Year Est. Return

Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return

OSAM

O'Shaughnessy Asset Management Stamford, Connecticut $20.1B AUM 30.42% 1-Year Est. Return

MCM

Monarch Capital Management Fort Wayne, Indiana $436M AUM 26.61% 1-Year Est. Return

CFA

CT Financial Advisors Chadds Ford, Pennsylvania $162M AUM 9.58% 1-Year Est. Return

UBS Group's ENZN Position: Q2 2016 in Review

UBS Group sold out of ENZON PHARMACEUTICALS INC (ENZN) in Q2 2016, closing a stake of 723,072 shares — an estimated $340K sold.

UBS Group first reported a position in ENZN in Q4 2014 and held it in 6 quarters. The position peaked at $850K in Q2 2015. 10 funds tracked by Wall St. Rank hold ENZN as of Q2 2016.

UBS Group reported no remaining ENZON PHARMACEUTICALS INC position as of Q2 2016 after selling out during the quarter.
UBS Group sold 723,072 ENZON PHARMACEUTICALS INC shares in Q2 2016, an estimated $340K.
UBS Group first reported a position in ENZON PHARMACEUTICALS INC in Q4 2014 and held it in 6 quarters.
UBS Group's ENZON PHARMACEUTICALS INC position peaked at $850K in Q2 2015.
10 funds tracked by Wall St. Rank held ENZON PHARMACEUTICALS INC as of Q2 2016.

Based on UBS Group's 13F filing for Q2 2016, filed 12 Aug 2016.